Skip to content

Study · Non-randomized trial · n = 11 · 1988

5 results

Subcutaneous treatment with growth hormone-releasing hormone for short stature.

Hernández M, Fragoso J, Barrio R, Argente J, Arilla E

Hormone research1 Jan 1988Cited by 5 (Europe PMC)

PMID2907992 (opens in a new tab)DOI10.1159/000181072 (opens in a new tab)PepBankPUB-02907992
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with short stature and normal GH secretion, the peak GH response to GRF bolus was 56.04 ng/ml before treatment and similar after 6 months of GRF.

    In plain wordsIn short children with normal growth hormone release, the peak response to a GRF test dose did not change after 6 months of treatment.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GH response to GRF bolus
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 micrograms/kg · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Peak plasma GH
    56.04 ng/ml
    before treatment

    Source sentences

    Summary
    The peak plasma GH level in response to GRF was 56.04 +/- (SD) 24.46 ng/ml before treatment, and similar results were found after therapy.
    2 context sentences
    Summary · context
    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secr…
    Summary · context
    All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with short stature, the 24-hour GH secretory profile did not differ before, during and after GRF treatment.

    In plain wordsIn short children with normal growth hormone release, the 24-hour growth hormone pattern did not change with GRF treatment.

    Peptide
    Sermorelin
    Outcome
    No significant change24-hour GH secretory profile
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 micrograms/kg · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The 24-hour GH secretory profile did not show differences before, during, and after treatment.
    2 context sentences
    Summary · context
    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secr…
    Summary · context
    All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with short stature, GH pulse frequency, amplitude, height, increment and area did not differ before and 6 months off GRF therapy.

    In plain wordsIn short children with normal growth hormone release, growth hormone pulse measures did not differ before treatment and 6 months after stopping.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH pulse characteristics
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 micrograms/kg · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Comparably, no differences were found in GH pulse frequency, pulse amplitude, pulse height, pulse increment, pulse area and total area before, and 6 months off therapy with GRF.
    2 context sentences
    Summary · context
    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secr…
    Summary · context
    All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with short stature, the increments in serum IGF-I during GRF treatment were not significantly different at any interval studied.

    In plain wordsIn short children with normal growth hormone release, IGF-I blood levels did not change significantly during GRF treatment.

    Peptide
    Sermorelin
    Outcome
    No significant changeSerum IGF-I increments
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 micrograms/kg · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The increments in serum IGF-I achieved were not significantly different at all intervals studied.
    2 context sentences
    Summary · context
    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secr…
    Summary · context
    All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with short stature and normal GH secretion, all patients increased growth velocity in response to GRF therapy.

    In plain wordsIn short children with normal growth hormone release, all 11 grew faster during GRF treatment, with no control group.

    Peptide
    Sermorelin
    Outcome
    IncreaseGrowth velocity
    Study

    n = 11

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    5 micrograms/kg · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    All patients increased growth velocities (mean +/- SD, cm/year) in response to GRF therapy.
    2 context sentences
    Summary · context
    In the present study we report the effects of therapy with growth hormone-releasing factor (1-29)NH2 (GRF) on growth rate, plasma levels of insulin growth factor I (IGF-I) and growth hormone (GH) secretion in 11 children who were selected solely on the basis of their short stature and normal GH secr…
    Summary · context
    All children received GRF for 6 months (5 micrograms/kg body weight subcutaneously) each evening.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.